Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

QR Code

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

<h4>Background</h4>This study aims to comprehensively summarize the currently available evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced pancreatic cancer.<h4>Methodology/principal findings</h4>PubMed, EMBASE, The Cochrane Library and a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zu-Yao Yang, Jin-Qiu Yuan, Meng-Yang Di, Da-Yong Zheng, Jin-Zhang Chen, Hong Ding, Xin-Yin Wu, Ya-Fang Huang, Chen Mao, Jin-Ling Tang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0057528
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Human Telomerase Reverse Transcriptase Gene Antisense Oligonucleotide Increases the Sensitivity of Pancreatic Cancer Cells to Gemcitabine In Vitro
by: Liu, Yong-ping, et al.
Published: (2012)

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer
by: Geng Xu, et al.
Published: (2025-07-01)

Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report
by: Yusuke Wakasa, et al.
Published: (2022-03-01)

A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer
by: Weiting Jiang, et al.
Published: (2025-10-01)

GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma
by: Tianyi Zhu, et al.
Published: (2025-07-01)

Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
by: Takahiro Murokawa, et al.
Published: (2022-02-01)

Galectin-3 in tumor-stromal cells enhances gemcitabine resistance in pancreatic adenocarcinoma by suppressing oxidative phosphorylation
by: Yaheng Wu, et al.
Published: (2025-09-01)

Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
by: Ryosuke Takayanagi, et al.
Published: (2017-11-01)

Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report
by: Yuya Miura, et al.
Published: (2022-01-01)

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
by: Xiaofeng Chen, et al.
Published: (2013-01-01)

Bullous fixed drug eruption due to erlotinib: A rare case report
by: Kallolinee Samal, et al.
Published: (2025-07-01)

First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience
by: Emrah Eraslan, et al.
Published: (2019-04-01)

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis
by: HE Yuan, GUO Juncheng, YE Zhibin, WANG Xiaohu, LI Haonan, HUANG Jingbiao
Published: (2025-06-01)

Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy
by: Miguel Pereira-Silva, et al.
Published: (2025-12-01)

A glycogen derived from sea urchin-Strongylocentyotus internedius shifts macrophages to the M1 phenotype and enhances the anti-pancreatic cancer activity of gemcitabine
by: Zhenzhen Deng, et al.
Published: (2025-07-01)

Laparoscopic Pancreatic Surgery
by: Jang, Jin-Young
Published: (2012)

Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection
by: Elyar Abaydulla, et al.
Published: (2025-12-01)

SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells
by: Jianguang Jin, et al.
Published: (2017-03-01)

One Step Closer to the Target: Intracellular Pharmacokinetics of Gemcitabine
by: Links, Matthew, et al.
Published: (2012)

CircRNAs modulate response of cancer cells to gemcitabine
by: Zahra Tajik, et al.
Published: (2025-12-01)

The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status
by: Abdullah Sakin, et al.
Published: (2019-12-01)

Botriomicosis asociada a tratamiento con erlotinib en una paciente con adenocarcinoma de pulmón
by: Claudia Montoya, et al.
Published: (2019-08-01)

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

Enhancing chemosensitivity of PANC1 pancreatic cancer cells to gemcitabine using ANGTPL4, Notch1 and NF-κβ1 siRNAs
by: Abdulfattah Al-Kadash, et al.
Published: (2024-12-01)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

Magnetically sensitive nanocomposites for targeted antitumor therapy with application of gemcitabine
by: N. M. Korniichuk, et al.
Published: (2020-11-01)

Synthesis and properties of magnetically sensitive nanocomposites based on magnetite and gemcitabine
by: A. L. Petranovska, et al.
Published: (2018-11-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Impact of smoking on the risk of pancreatitis: a systematic review and meta-analysis.
by: Xiaohua Ye, et al.
Published: (2015-01-01)

Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer
by: Huake Sun, et al.
Published: (2017-07-01)

Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity
by: Aashita, et al.
Published: (2025-04-01)

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
by: Mitsuru Kinoshita, et al.
Published: (2022-09-01)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

Intramolecular Versus Intermolecular Bonding in Drug Gemcitabine and Nucleobases: A Computational Study
by: Natarajan Sathiyamoorthy Venkataramanan, et al.
Published: (2025-06-01)

Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities
by: Ling Yin, et al.
Published: (2025-07-01)

Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: protocol of single-arm, open-label, phase II trial (Nab-PIPAC trial)
by: Di Giorgio Andrea, et al.
Published: (2024-11-01)

A patient with adenocarcinoma of the pancreas nearly cured by albumin-bound gemcitabine + tegafur, gimeracil and oteracil potassium in combination with carrelizumab
by: Bao-long Dong, et al.
Published: (2025-08-01)

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
by: Jiro Kimura, et al.
Published: (2022-05-01)

Magnetically sensitive nanocomposites and magnetic liquids based on magnetite, gemcitabine, and antibody HER2
by: A. L. Petranovska, et al.
Published: (2019-11-01)